Table 2.
Univariate and multivariate analysis of prognostic factors for OS in newly diagnosed patients with DLBCL
| Parameters | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Sex (male vs. female) | 1.26 | 0.91–1.75 | 0.165 | |||
| Age (>60 vs. ≤60) | 1.49 | 1.09–2.04 | 0.014 | 1.25 | 0.88–1.76 | 0.215 |
| Ann Arbor Stage (III–IV vs. I–II) | 2.65 | 1.78–3.95 | <0.001 | 1.39 | 0.87–2.23 | 0.166 |
| Extranodal disease (>1 vs ≤1) | 1.87 | 1.36–2.56 | <0.001 | 1.09 | 0.76–1.55 | 0.645 |
| ECOG score (2–4 vs. 0–1) | 3.01 | 2.19–4.15 | <0.001 | 1.83 | 1.24–2.70 | 0.002 |
| LDH (>ULN vs. normal) | 3.13 | 2.21–4.42 | <0.001 | 1.93 | 1.29–2.88 | 0.001 |
| B symptoms (present vs. absent) | 2.27 | 1.65–3.13 | <0.001 | 1.28 | 0.89–1.85 | 0.180 |
| Serum ApoA1 (high vs. low) | 0.39 | 0.28–0.53 | <0.001 | 0.66 | 0.46–0.94 | 0.022 |
| Subtype (non-GCB vs. GCB) | 1.76 | 1.21–2.57 | 0.003 | 1.38 | 1.04–1.83 | 0.024 |
| Regimen (CHOP-like vs. R-CHOP-like) | 2.00 | 1.38–2.90 | <0.001 | 2.21 | 1.51–3.23 | <0.001 |
CI Confidence interval, HR Hazard ratio, ECOG Eastern Cooperative Oncology Group, LDH Lactate dehydrogenase, ULN Upper limit of normal, ApoA1 Apolipoprotein A1, GCB Germinal center B-cell-like